

INDGN/SE/2024-25/113

February 24, 2025

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
-------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir / Madam,

Sub: Indegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is a press release dated February 24, 2025, titled 'Indegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry'.

The above information will be made available on the website of the Company: <https://www.indegene.com/>

A copy of the Press Release is enclosed for your reference.

This is for your information and records.

For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance officer



Indegene Limited (Formerly Indegene Private Limited),
Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: U73100KA1998PLC102040



Press Release

Indegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry

Bengaluru, India and Princeton, US, February 24, 2025: Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.

This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domain-friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM state-of-the-art improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration.

Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement.

"Life sciences leaders believe in GenAI's potential to transform and modernize their commercialization processes," said Manish Gupta, Chairperson and CEO, Indegene. "They also demand an enterprise-grade platform that assures them of the security, governance, scalability and business value essential to adopting technology across the enterprise. With this GenAI platform, we codify our 25+ years of practitioner experience letting life sciences leaders make the most of this transformative technology."

Tarun Mathur, CTO, Indegene, added, "Life sciences leaders demand an AI infrastructure that adapts to new business models, processes and experiences. Our new GenAI platform empowers them to develop their own intellectual property (IP), leveraging Indegene's technology and knowledge engineering practices. We look forward to supporting the wide number of use cases they apply this exciting technology to and the value they realize in the process."

Leading industry analysts recognize Indegene's bold vision and market impact in adopting and scaling GenAI in the life sciences industry. HFS Research, a global business research consultancy [recognized](#) Indegene as a Horizon 3 OneEcosystem Exponential Leader for leveraging GenAI to collaborate across the life sciences and healthcare ecosystem to improve health outcomes, enhance stakeholder experience and optimize costs. Everest Group, a leading research and advisory firm [identified](#) Indegene as a Front-Runner for scaling GenAI, capturing industry-specific use cases, building partnerships and delivering value. To learn more about Cortex and how Indegene is enabling life sciences leaders to realize GenAI's potential, please visit www.indegene.com/what-we-do/cortex



About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com

For media inquiries, please contact:

Yadunandan K V | yadunandan.kv@indegene.com